CRISPR Therapeutics AG (CRSP)
Data as of , from SEC Form 4 filings.
See up to 3 months of CRSP. The 7-day demo opens the 1M and 3M ranges and puts CRSP on your watchlist.
Start 7-day demoLatest CRSP insider trades
James R. Kasinger - OfficerOpen-market sale$119K- James R. Kasinger - OfficerOpen-market sale
About CRISPR Therapeutics AG (CRSP)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
- ZUG
- 393
- 2016
- XNAS
CRSP Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 12,390 | $746K |
| Option exercise | 4 | 24,780 | |
| Bona-fide gift | 1 | 750 | |
CRSP insider transactions (Form 4)
5857 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Naimish Patel - Officer | Open-market purchase | Common Shares | 1,508 | $32.96 | $50K | |
 Raju Prasad - Officer | Option exercise | Common Shares | 34,972 | $45.15 | $1.58M | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 34,972 | $60.19 footnote F2 | $2.10M | |
| Raju Prasad - Officer | Option exercise | Stock Option (Right to Buy) | 34,972 | $0.00 | - | |
| ||||||
 Samarth Kulkarni - Officer | Open-market sale | Common Shares | 21,433 | $51.61 footnote F2 | $1.11M | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 8,567 | $52.10 footnote F3 | $446K | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 60,000 | $60.23 footnote F4 | $3.61M | |
| ||||||
| Raju Prasad - Officer | Option exercise | Common Shares | 23,361 | $45.15 | $1.05M | |
| Raju Prasad - Officer | Option exercise | Common Shares | 6,339 | $44.31 | $281K | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 18,933 | $60.18 footnote F2 | $1.14M | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 5,004 | $60.00 | $300K | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 5,763 | $60.21 footnote F3 | $347K | |
| Raju Prasad - Officer | Option exercise | Stock Option (Right to Buy) | 23,361 | $0.00 | - | |
| Raju Prasad - Officer | Option exercise | Stock Option (Right to Buy) | 6,339 | $0.00 | - | |
| ||||||
| Raju Prasad - Officer | Open-market sale | Common Shares | 3,528 | $55.10 footnote F2 | $194K | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 5,472 | $56.33 footnote F3 | $308K | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 1,000 | $56.89 footnote F4 | $57K | |
| ||||||
| Samarth Kulkarni - Officer | Gift | Common Shares | 30,000 | $0.00 | - | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 100,000 | - footnote F1 | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 50,895 footnote F2 | $67.91 | $3.46M | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 100,000 | - footnote F1 | - | |
| ||||||
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 8,334 | - footnote F1 | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 4,242 footnote F2 | $66.60 | $283K | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 8,334 | - footnote F1 | - | |
| ||||||
| James R. Kasinger - Officer | Option exercise | Common Shares | 2,114 | - footnote F1 | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 1,076 footnote F3 | $66.60 | $72K | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 2,114 | - footnote F1 | - | |
| ||||||
| Samarth Kulkarni - Officer | Grant or award | Stock Option (Right to Buy) | 49,500 | $0.00 | - | |
| Naimish Patel - Officer | Grant or award | Stock Option (Right to Buy) | 16,500 | $0.00 | - | |
| James R. Kasinger - Officer | Grant or award | Stock Option (Right to Buy) | 16,500 | $0.00 | - | |
| Raju Prasad - Officer | Grant or award | Stock Option (Right to Buy) | 16,500 | $0.00 | - | |
| Samarth Kulkarni - Officer | Gift | Common Shares | 6,000 | $0.00 | - | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 25,000 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 13,081 | $58.15 | $761K | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 25,000 | - | - | |
| Douglas A. Treco | Open-market purchase | Common Shares | 20,000 | $57.03 | $1.14M | |
| Simeon George | Open-market purchase | Common Shares | 6,510 | $52.03 | $339K | |
| Simeon George | Open-market purchase | Common Shares | 22,319 | $52.03 | $1.16M | |
| Simeon George | Open-market purchase | Common Shares | 960,983 | $52.03 | $50.00M | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 13,751 | $16.21 | $223K | |
| Samarth Kulkarni - Officer | Option exercise | Stock Option (Right to Buy) | 13,751 | $0.00 | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 15,000 | $55.10 | $827K | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 23,121 | $55.43 | $1.28M | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 6,879 | $56.27 | $387K | |
| Naimish Patel - Officer | Grant or award | Stock Option (Right to Buy) | 18,333 | $0.00 | - | |
| James R. Kasinger - Officer | Grant or award | Stock Option (Right to Buy) | 18,333 | $0.00 | - | |
| James R. Kasinger - Officer | Grant or award | Restricted Stock Units | 30,000 | $0.00 | - | |
| Julianne Bruno - Officer | Grant or award | Stock Option (Right to Buy) | 18,333 | $0.00 | - | |
| Samarth Kulkarni - Officer | Grant or award | Stock Option (Right to Buy) | 55,000 | $0.00 | - | |
| Samarth Kulkarni - Officer | Grant or award | Restricted Stock Units | 400,000 | $0.00 | - | |
| Raju Prasad - Officer | Grant or award | Stock Option (Right to Buy) | 18,333 | $0.00 | - | |
| Raju Prasad - Officer | Grant or award | Restricted Stock Units | 15,000 | $0.00 | - | |
| James R. Kasinger - Officer | Option exercise | Common Shares | 2,113 | - | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 1,089 | $46.28 | $50K | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 2,113 | - | - | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 8,333 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 4,293 | $46.28 | $199K | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 8,333 | - | - | |
Item 2.02, 9.01
Item 5.02, 5.03, 5.07, 9.01
Item 2.02, 9.01
Item 1.01, 2.03, 3.02, 9.01
Recent CRSP Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| JAMES KASINGER | Officer | 1,990 | $119K | View on EDGAR | |
| JAMES KASINGER | Officer | 10,400 |
CRSP insider trading FAQ
What is the latest insider trade for CRSP?
CRISPR Therapeutics AG (CRSP) had 4 insider filings in the last 90 days, with the most recent on 2026-10-08. The full record for CRSP runs to 57 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CRSP stock?
No insider purchases of CRSP were filed in the last 90 days. 5 purchases are on record for this company.
How many insiders are selling CRSP stock?
2 insider sales of CRSP were filed in the last 90 days, totaling $746K.
Where can I see CRSP SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CRSP Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - James R. Kasinger view on EDGAR
- - James R. Kasinger view on EDGAR
- - Ali Behbahani view on EDGAR
- - Raju Prasad view on EDGAR
- - Simeon George view on EDGAR
- - Ali Behbahani view on EDGAR
- - Maria Fardis view on EDGAR
- - Harold Edward Fleming view on EDGAR
- - John Greene view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CRSP's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CRSP with a 7-day demo
- CRSP on your watchlist
- Every CRSP Form 4 filing on record
- Up to 3 months of CRSP price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
